Stock·NYSE·Healthcare
McKesson Corporation (MCK)
- Market cap
- $117.15B
- P/E
- 26.77
- Dividend yield
- 0.34%
- Street target
- $1,000.00median of 15 analysts
- 52-week range
- $723.68 $1,014.99
The short version
Where MCK stands today, in four lines, and what CleaRank Financial AI makes of it.
MCK at a glance
McKesson Corporation (MCK): Buy, 75/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($896.43 and $853.97).
- Earnings MCK beat estimates in 8 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $83.7M and made no open-market purchases over the last 18 months.
- Valuation P/E of 26.8 against 31.9 for the Healthcare sector: broadly in line with peers (-16%).
Figures as of October 17, 2026.
CleaRank Financial AI
McKesson Corporation (MCK) earns a CleaRank rating of Buy with a model score of 75/100.
Its trend contributes the most to that score: the price is 17.67% above its 200-day average and 12.09% above its 50-day average, and the 50-day average is 4.97% above the 200-day. Profitability pulls the score down the most, since return on equity of -570.98% is below the sector median. The 50-day average is $896.43 and the 200-day average is $853.97. The price rose 29.58% over the past year.
Only on CleaRank
Figures we compute ourselves from MCK's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $1,004.84 is 12.1% above the 50-day simple moving average of $896.43.Price above its 200-day average ›
The price is 17.7% above the 200-day simple moving average of $853.97.50-day average above the 200-day ›
The 50-day average ($896.43) is 5.0% above the 200-day average ($853.97), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 97% of its 52-week range, between $723.68 and $1,014.99.
MCK share price
Pick a period: each tab shows how far MCK has moved over it, to the last close.
Today's trading
Where MCK sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 26.77 is 16.1% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 0.28 is 91.7% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $4.6B on revenue of $411.0B, a net margin of 1.1%.Beat estimates in most recent reports ›
MCK beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 0.34%, or $3.40 a share a year.
Key statistics
The headline figures for MCK.
As of October 17, 2026, MCK trades at $1,004.84, with a market value of $117.15B, a P/E ratio of 26.77 and a dividend yield of 0.34%.
What the numbers say
CleaRank Financial AI's reading of MCK's valuation, growth and risks.
McKesson Corporation (MCK) trades at 26.77 times trailing earnings, which is 16.1% below the Healthcare median of 31.9. The peer comparison on this page rates that P/E as broadly in line with peers. On sales, the P/S of 0.28 is 91.8% below the sector median of 3.4. Trailing earnings per share stand at $37.31.
Revenue grew 7.70% over the latest year, which is 0.4 percentage points behind the 8.1% median for Healthcare. MCK turns sales into profit at a net margin of 1.12% and an operating margin of 1.35%, alongside a return on equity of -570.98%, below the sector median of 7.3%. It also reports a trailing dividend yield of 0.34% ($3.40 a share a year).
MCK's most recent earnings report, released on August 5, 2026, showed EPS of $9.93 against the $9.54 analysts had forecast. That was a beat of 4.09%. The share price nonetheless dropped 0.67% in the first session after the report.
MCK has beaten the EPS estimate in all 8 of its recent reports, though the stock still fell in the first session after 4 of those 8 beats. Analysts' average EPS estimate for this fiscal year is $44.68, which would be growth of 14.2%, and $50.59 for next year (growth of 13.2%).
Normal swings for MCK run at about 1.62% a day. Over the last 18 months, insider sales totalled $83.7M with no open-market purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
MCK against the Healthcare sector
How MCK compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-16% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 6, 2025, MCK has gained 41.3% against a gain of 31.6% for XLV.
Performance against XLV
MCK and the Healthcare sector fund over the same days.
Revenue and earnings
How much MCK sells, and how much of it becomes profit.
Revenue growth: Revenue grew 12.4% in FY2026 to $403B, from $359B a year earlier.
Profit margin: The net margin was 1.3% in FY2026, up from 1.0% the year before.
Profitable: MCK earned $5.1B in FY2026.
Earnings reality check
Did MCK beat what analysts expected, and how did the stock react?
Earnings record: MCK beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | $9.54 | $9.93 | +4.09% | -0.67% | +0.17% |
| May 7, 2026after close | $11.57 | $11.69 | +1.04% | -2.47% | -1.00% |
| Feb 4, 2026after close | $9.27 | $9.34 | +0.76% | +16.52% | +15.96% |
| Nov 5, 2025after close | $9.05 | $9.86 | +8.95% | +1.70% | -0.42% |
| Aug 6, 2025after close | $8.15 | $8.26 | +1.35% | -5.76% | -5.77% |
| May 8, 2025after close | $9.83 | $10.12 | +2.95% | +0.47% | +2.39% |
| Feb 5, 2025after close | $7.99 | $8.03 | +0.50% | -1.18% | -1.96% |
| Nov 6, 2024after close | $6.87 | $7.07 | +2.91% | +10.60% | +13.71% |
As of October 17, 2026, MCK has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on August 5, 2026, came in 4.09% above the estimate and the stock moved -0.67% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 75.7, in overbought territory.RSI above 50 ›
An RSI of 75.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of MCK
The score, the reasoning behind it, and what could move the price next.
McKesson Corporation (MCK) is in an uptrend. The price of $1,004.84 sits 17.67% above its 200-day average of $853.97 and 12.09% above its 50-day average of $896.43. Its place in the 52-week range is 97%, and the price is 1.00% below the 52-week high of $1,014.99.
Momentum is strong on the chart. The 14-day RSI stands at 75.7, which is in the overbought zone, and the MACD line is positive. Gains have shown up in every period measured, with the stock up 19.43% over three months, 15.98% over six months and 29.58% over the past year.
Earnings beat ›
The August 5, 2026 report beat the EPS estimate by 4.09%, and the share price fell 0.67% in the first session after it.
Source: Earnings report, August 5, 2026Rating reaffirmed ›
Leerink Partners kept its Outperform rating on October 7, 2026.
Source: Analyst action, Leerink Partners, October 7, 2026
New analyst coverage ›
RBC Capital started coverage at Sector Perform on August 19, 2026.
Source: Analyst action, RBC Capital, August 19, 2026
- Keep an eye on the two levels nearest the price: the 52-week high at $1,014.99 overhead, and the 20-day EMA at $931.25 underneath.
- The 14-day RSI is 75.7, which is in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 signal stretched momentum.
- The share price fell 0.67% in the first session after the August 5, 2026 report. Across the last 8 reports, MCK has beaten estimates each time.
MCK trades above its 50-day and 200-day moving averages ($896.43 and $853.97), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 20-day EMA at $931.25.
The next level overhead is the 52-week high of $1,014.99. The RSI is in overbought territory, so a pause in the rally would not by itself break the trend. A slide out of the bullish zone would be the sign that momentum is weakening.
Technical indicators
Momentum and trend for MCK, from its daily closes.
As of October 17, 2026, with MCK at $1,004.84, its 14-day RSI is 75.7 (overbought territory), its 50-day simple moving average is $896.43 and its 200-day is $853.97.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What MCK moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, MCK's 1-year correlation of daily returns is +0.03 with S&P 500 (SPY), -0.07 with Nasdaq 100 (QQQ), -0.23 with Bitcoin (BTC) and +0.00 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
12 of 15 analysts rate it a buy or strong buy, 3 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $1,000.00 is 0.5% below the price.More buy ratings than three months ago ›
12 of 15 rate it a buy now, against 14 of 17 three months ago.
MCK Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Leerink Partners | Maintains | Outperform |
| Sep 14, 2026 | RBC Capital | Reiterates | Sector Perform |
| Aug 19, 2026 | Barclays | Maintains | Overweight |
| Aug 19, 2026 | RBC Capital | Initiates | Sector Perform |
| Aug 11, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Aug 6, 2026 | TD Cowen | Maintains | Buy |
As of October 17, 2026, 15 Wall Street analysts cover MCK: 12 rate it a buy or strong buy, 3 a hold and 0 a sell or strong sell. Their 12-month price targets range from $845.00 to $1,070.00, with a median of $1,000.00, 0.5% below the price of $1,004.84.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
MCK trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from MCK's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much MCK tends to move, against the market and on its own.
The long record
MCK's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.62% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 37.6%, from January 2018 to December 2018, regained by November 2020.Most 1-year holds ended higher ›
86% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $67,478, against $42,055 in the S&P 500 (SPY).
MCK Drawdowns & Recovery
As of October 17, 2026, MCK's worst peak-to-trough fall over the last 10 years with dividends reinvested was -37.6% (January 2018 to December 2018); it regained that peak by November 2020, 23 months after the low, and 86% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into MCK in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: MCK beat the S&P 500 over this period: $67,478 against $42,055.
A $10,000 investment in MCK in October 2016 would be worth about $67,478 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to MCK, and which have not.
Strongest month, November: an average of +9.54%, up in 9 of 10 years.
Weakest month, December: an average of -1.73%, up in 3 of 10 years.
This month, October: has averaged -0.31%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, MCK's strongest calendar month has been November (average +9.54%, up in 9 of 10 years) and its weakest December (average -1.73%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in MCK, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MCK today could grow to about $26,564 by 2036 in the base case, with a 90th-percentile outcome near $87,071 and a 10th-percentile outcome around $8,104. The simulation models price only; at today's 0.34% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
MCK Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $1,485 for MCK by 2030 in the base case, from $1,005 today (1.5x over 4 years). The 10th-percentile path ends near $701. These are outcomes of a Monte Carlo simulation run on MCK's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $761 | $1,108 | $1,613 | |
| 2028 | $718 | $1,222 | $2,077 | |
| 2029 | $703 | $1,347 | $2,581 | |
| 2030 | $701 | $1,485 | $3,147 | |
| 2031 | $707 | $1,638 | $3,792 |
Method: a lognormal simulation of MCK's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
MCK insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought MCK shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, MCK insiders reported 33 open-market sales worth $83.7M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Napoleon B Rutledge Jr
Officer
|
Sell | 111 | $99.0K |
| Aug 10, 2026 | Bradley E Lerman
Director
|
Sell | 301 | $268.6K |
| Jul 22, 2026 | Dominic J Caruso
Director
|
Grant | 277 | $225.5K |
| Jul 22, 2026 | Maria N. Martinez
Director
|
Grant | 277 | $225.5K |
| Jul 22, 2026 | - Thompson Kathleen Wilson
Director
|
Grant | 277 | $225.5K |
| Jul 7, 2026 | Brian Scott Tyler
Chief Executive Officer
|
Sell | 8.5K | $6.7M |
| Jun 17, 2026 | Brian Scott Tyler
Chief Executive Officer
|
Sell | 8.5K | $6.6M |
| Jun 9, 2026 | Brian Scott Tyler
Chief Executive Officer
|
Sell | 4.9K | $3.8M |
| Jun 5, 2026 | Napoleon B Rutledge Jr
Officer
|
Sell | 133 | $101.6K |
| Jun 2, 2026 | Thomas L Rodgers
Officer
|
Sell | 822 | $604.4K |
| Jun 1, 2026 | Leann B Smith
Officer
|
Sell | 1.8K | $1.3M |
| May 26, 2026 | Michele Lau
Officer
|
Sell | 3.6K | $2.7M |
| May 26, 2026 | Thomas L Rodgers
Officer
|
Sell | 2.4K | $1.8M |
| May 22, 2026 | Francisco Fraga
Chief Technology Officer
|
Grant | 136 | - |
| May 22, 2026 | Thomas L Rodgers
Officer
|
Grant | 594 | - |
| May 22, 2026 | Napoleon B Rutledge Jr
Officer
|
Grant | 136 | - |
| May 22, 2026 | Leann B Smith
Officer
|
Grant | 679 | - |
| May 22, 2026 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 4.6K | - |
| May 22, 2026 | Britt J Vitalone
Chief Financial Officer
|
Grant | 1.5K | - |
| May 21, 2026 | Francisco Fraga
Chief Technology Officer
|
Grant | 483 | - |
| May 21, 2026 | Michele Lau
Officer
|
Grant | 724 | - |
| May 21, 2026 | Thomas L Rodgers
Officer
|
Grant | 423 | - |
| May 21, 2026 | Napoleon B Rutledge Jr
Officer
|
Grant | 91 | - |
| May 21, 2026 | Leann B Smith
Officer
|
Grant | 531 | - |
| May 21, 2026 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 3.5K | - |
| May 21, 2026 | Britt J Vitalone
Chief Financial Officer
|
Grant | 1.2K | - |
| May 20, 2026 | Francisco Fraga
Chief Technology Officer
|
Grant | 463 | - |
| May 20, 2026 | Michele Lau
Officer
|
Grant | 677 | - |
| May 20, 2026 | Thomas L Rodgers
Officer
|
Grant | 324 | - |
| May 20, 2026 | Napoleon B Rutledge Jr
Officer
|
Grant | 74 | - |
| May 20, 2026 | Leann B Smith
Officer
|
Grant | 463 | - |
| May 20, 2026 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 3.2K | - |
| May 20, 2026 | Britt J Vitalone
Chief Financial Officer
|
Grant | 1.0K | - |
| May 19, 2026 | Francisco Fraga
Chief Technology Officer
|
Grant | 3.1K | - |
| May 19, 2026 | Michele Lau
Officer
|
Grant | 4.5K | - |
| May 19, 2026 | Thomas L Rodgers
Officer
|
Grant | 3.6K | - |
| May 19, 2026 | Napoleon B Rutledge Jr
Officer
|
Grant | 788 | - |
| May 19, 2026 | Leann B Smith
Officer
|
Grant | 4.1K | - |
| May 19, 2026 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 27.9K | - |
| May 19, 2026 | Britt J Vitalone
Chief Financial Officer
|
Grant | 9.0K | - |
| Mar 2, 2026 | Michele Lau
Officer
|
Sell | 2.7K | $2.7M |
| Feb 19, 2026 | Maria N. Martinez
Director
|
Sell | 349 | $328.0K |
| Feb 17, 2026 | Leann B Smith
Officer
|
Sell | 190 | $179.6K |
| Feb 11, 2026 | Michele Lau
Officer
|
Sell | 303 | $282.8K |
| Feb 10, 2026 | Leann B Smith
Officer
|
Grant | 508 | - |
| Feb 9, 2026 | Michele Lau
Officer
|
Grant | 4.7K | - |
| Feb 6, 2026 | Napoleon B Rutledge Jr
Officer
|
Sell | 328 | $313.2K |
| Jan 5, 2026 | Thomas L Rodgers
Officer
|
Sell | 276 | $225.3K |
| Nov 7, 2025 | Napoleon B Rutledge Jr
Officer
|
Sell | 329 | $283.5K |
| Aug 22, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Sell | 11.9K | $8.4M |
| Aug 15, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Sell | 11.9K | $8.1M |
| Aug 8, 2025 | Napoleon B Rutledge Jr
Officer
|
Sell | 329 | $218.3K |
| Jul 30, 2025 | Dominic J Caruso
Director
|
Grant | 301 | - |
| Jul 30, 2025 | Bradley E Lerman
Director
|
Grant | 301 | - |
| Jul 30, 2025 | Maria N. Martinez
Director
|
Grant | 301 | - |
| Jul 30, 2025 | - Thompson Kathleen Wilson
Director
|
Grant | 301 | - |
| Jul 11, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Sell | 19.4K | $13.7M |
| Jun 10, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 4.0K | - |
| Jun 6, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Sell | 19.4K | $13.7M |
| May 30, 2025 | Thomas L Rodgers
Officer
|
Sell | 2.9K | $2.1M |
| May 28, 2025 | Britt J Vitalone
Chief Financial Officer
|
Sell | 1.9K | $1.3M |
| May 28, 2025 | Thomas L Rodgers
Officer
|
Sell | 510 | $366.1K |
| May 28, 2025 | Leann B Smith
Officer
|
Sell | 341 | $244.8K |
| May 28, 2025 | Napoleon B Rutledge Jr
Officer
|
Sell | 95 | $68.2K |
| May 27, 2025 | Napoleon B Rutledge Jr
Officer
|
Sell | 1.0K | $749.4K |
| May 23, 2025 | Britt J Vitalone
Chief Financial Officer
|
Sell | 732 | $523.6K |
| May 23, 2025 | Leann B Smith
Officer
|
Sell | 161 | $115.2K |
| May 23, 2025 | Thomas L Rodgers
Officer
|
Grant | 1.2K | - |
| May 23, 2025 | Napoleon B Rutledge Jr
Officer
|
Grant | 136 | - |
| May 23, 2025 | Leann B Smith
Officer
|
Grant | 1.1K | - |
| May 23, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 9.9K | - |
| May 23, 2025 | Britt J Vitalone
Chief Financial Officer
|
Grant | 3.1K | - |
| May 22, 2025 | Britt J Vitalone
Chief Financial Officer
|
Sell | 6.3K | $4.5M |
| May 22, 2025 | Leann B Smith
Officer
|
Sell | 1.2K | $895.2K |
| May 21, 2025 | Michele Lau
Officer
|
Grant | 724 | - |
| May 21, 2025 | Thomas L Rodgers
Officer
|
Grant | 422 | - |
| May 21, 2025 | Napoleon B Rutledge Jr
Officer
|
Grant | 90 | - |
| May 21, 2025 | Leann B Smith
Officer
|
Grant | 531 | - |
| May 21, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 3.5K | - |
| May 21, 2025 | Britt J Vitalone
Chief Financial Officer
|
Grant | 1.2K | - |
| May 20, 2025 | Thomas L Rodgers
Officer
|
Grant | 3.7K | - |
| May 20, 2025 | Leann B Smith
Officer
|
Grant | 3.9K | - |
| May 20, 2025 | Brian Scott Tyler
Chief Executive Officer
|
Grant | 32.8K | - |
| May 20, 2025 | Britt J Vitalone
Chief Financial Officer
|
Grant | 10.1K | - |
| May 19, 2025 | Napoleon B Rutledge Jr
Officer
|
Sell | 543 | $394.5K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.